Saxenda and Victoza are two brand names for the same molecule — liraglutide — made by the same manufacturer (Novo Nordisk), in two different prefilled pens with different maximum doses and different FDA-approved indications. Saxenda is for chronic weight management; Victoza is for type 2 diabetes. This guide explains why one molecule has two products, what the practical differences are, and which one fits which patient.
Saxenda vs Victoza Side by Side
| Feature | Saxenda | Victoza |
|---|---|---|
| Active ingredient | Liraglutide | Liraglutide |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maximum daily dose | 3.0 mg | 1.8 mg |
| FDA-approved indication | Chronic weight management | Type 2 diabetes |
| Pediatric approval | Adolescents 12 to 17 with BMI 95th percentile or above | Children 10 and older with type 2 diabetes |
| Eligibility criteria | Adults BMI 30+, or BMI 27+ with comorbidity | Inadequate glycemic control on diet, exercise, and oral agents |
| Average weight loss (clinical trials) | about 8 percent body weight (SCALE) | about 2 to 3 kg |
| A1C reduction | about 0.5 percent (people with prediabetes/T2D) | about 1.0 to 1.5 percent |
| CV outcomes trial | Not dedicated CVOT | LEADER (MACE reduction of about 13 percent) |
| Dosing schedule | 0.6 – 1.2 – 1.8 – 2.4 – 3.0 mg over 5 weeks | 0.6 – 1.2 – 1.8 mg over 2+ weeks |
| List price (monthly) | about $1,300 to $1,600 | about $850 |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
Why One Molecule, Two Products?
Liraglutide acts on GLP-1 receptors throughout the body. Higher doses produce more appetite suppression, slower gastric emptying, and greater weight loss — but also more side effects. The 1.8 mg dose was developed and approved first for type 2 diabetes (Victoza, 2010). Researchers then tested progressively higher doses for obesity. The 3.0 mg dose proved to be the dose that maximized weight loss while remaining tolerable for most people. Because the dose, indication, prescribing population, insurance coverage, and pricing are different, Novo Nordisk packages the same molecule as two separate products.
FDA-Approved Indications
- Saxenda — chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in:
- Adults with BMI 30 or higher (obesity)
- Adults with BMI 27 or higher (overweight) plus at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia
- Adolescents 12 to 17 with body weight above 60 kg and BMI corresponding to 30 kg/m squared for adults
- Victoza — adjunct to diet and exercise to improve glycemic control in:
- Adults with type 2 diabetes
- Children 10 and older with type 2 diabetes
Also indicated to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
What Patients Often Get Confused About
- “I’m taking Victoza for diabetes — will I also lose weight?” Some, but modestly. Expect 2 to 3 kg over 6 to 12 months. Victoza is not titrated to a weight-loss dose.
- “I’m taking Saxenda for weight loss — will it also lower my blood sugar?” Yes, but it is not FDA-approved or labeled for that indication. People with type 2 diabetes generally are not switched from a diabetes drug to Saxenda unless weight management is the primary goal.
- “Can I get Victoza for weight loss?” Generally no. Insurance approval is tied to the FDA-approved indication. Off-label prescribing happens but is not the standard of care; the dose is not titrated to optimize weight loss.
- “Can I get Saxenda for diabetes?” Saxenda will lower glucose, but insurance typically covers it only for the weight management indication, and it is more expensive than Victoza. People with both diabetes and obesity are usually prescribed a single agent with appropriate dosing.
Efficacy Comparison
| Outcome | Saxenda 3.0 mg | Victoza 1.8 mg |
|---|---|---|
| Weight loss at 1 year | about 8 percent body weight | about 2 to 3 kg (around 3 percent) |
| 5 percent weight loss achieved | 63 percent of users | about 30 percent of users |
| 10 percent weight loss achieved | 33 percent of users | about 12 percent of users |
| A1C reduction (in T2D) | about 1.3 percent | about 1.0 to 1.5 percent |
Side Effects Compared
| Side Effect | Saxenda 3.0 mg | Victoza 1.8 mg |
|---|---|---|
| Nausea | about 39 percent | about 28 percent |
| Diarrhea | about 20 percent | about 17 percent |
| Constipation | about 19 percent | about 10 percent |
| Vomiting | about 16 percent | about 11 percent |
| Headache | about 14 percent | about 9 percent |
| Decreased appetite | about 10 percent | about 11 percent |
Saxenda’s higher dose produces somewhat higher rates of gastrointestinal side effects. Both share the same serious-but-uncommon risks: acute pancreatitis, gallbladder disease, acute kidney injury from dehydration, and the boxed warning for thyroid C-cell tumors.
Cost and Insurance
Saxenda is substantially more expensive than Victoza at retail — roughly $1,300 to $1,600 per month vs about $850 — because weight management drugs face different coverage policies than diabetes drugs. Many insurance plans cover Victoza readily for type 2 diabetes; Saxenda often requires demonstrating a BMI threshold and lifestyle counseling, and many plans (including most Medicare Part D plans) historically did not cover weight management drugs at all. The recent SELECT cardiovascular outcomes data and the broader Wegovy precedent are shifting coverage policies.
Pediatric Considerations
- Saxenda is approved for adolescents 12 to 17 with body weight above 60 kg and a BMI corresponding to adult obesity. Trial data from ages 12 to 17 showed about 4.6 percent greater BMI reduction than placebo at 56 weeks.
- Victoza is approved for children 10 and older with type 2 diabetes — the only injectable GLP-1 RA approved in this age group.
Switching Between Saxenda and Victoza
Direct switching is not typical because the indications differ. However:
- A person who started Saxenda for weight loss and is later diagnosed with type 2 diabetes might transition to a diabetes-indicated GLP-1 RA (Victoza, Ozempic, Trulicity, Rybelsus) or continue Saxenda if the weight goal continues.
- A person on Victoza for type 2 diabetes who needs greater weight loss might be switched to Wegovy (semaglutide for weight management) or higher-dose GLP-1 agents rather than to Saxenda, given equivalent or better outcomes per dollar with weekly semaglutide.
- Dose escalation from Victoza 1.8 mg to Saxenda 3.0 mg requires going through the 2.4 mg step over a week to two; this is done under clinician guidance.
Who Should Choose Which
- Choose Saxenda if: the primary goal is weight loss, BMI criteria are met, no type 2 diabetes is present (or weight management is the priority), insurance covers anti-obesity drugs, and adolescent dosing is needed for ages 12 to 17.
- Choose Victoza if: the primary goal is type 2 diabetes management, cardiovascular benefit in established CV disease is sought, pediatric type 2 diabetes (age 10+) is the diagnosis, or insurance covers diabetes drugs but not weight management drugs.
Related Reading
For more on these and related medications, see our pages on Saxenda for weight loss, Saxenda side effects, Victoza for type 2 diabetes, Victoza versus Ozempic, and the GLP-1 drug class overview. For broader context, see our treatment hub and is prediabetes reversible. The current treatment framework is summarized in the ADA Standards of Care 2024.
The Bottom Line
Saxenda and Victoza are the same molecule — liraglutide — packaged for two different jobs. Saxenda at 3.0 mg daily is for chronic weight management; Victoza at up to 1.8 mg daily is for type 2 diabetes (and cardiovascular risk reduction in established CV disease). The higher Saxenda dose produces about 8 percent body weight loss versus 2 to 3 kg for Victoza, with somewhat higher side-effect rates. Both share the GLP-1 class profile and boxed thyroid C-cell tumor warning. Choose based on indication, age, comorbidities, and insurance coverage — with input from your clinician.
